Journal Club

20222021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011

 

2022

Diagnostic parameters of cellular tests for Lyme borreliosis in Europe (VICTORY study): a case-control study

15.8.2022 (Aurélien Martinez)

Baarsma et al.: Diagnostic parameters of cellular tests for Lyme borreliosis in Europe (VICTORY study): a case-control study Lancet Infectious diseases (online) 2022

A prospective randomized study comparing Ceftolozane/Tazobactam to Standard of Care in the Management of Neutropenia and Fever in Patients with Hematological Malignancies05.09.2022 (Michelle Baumann)

Chaftari AM et al.: A prospective randomized study comparing Ceftolozane/Tazobactam to Standard of Care in the Management of Neutropenia and Fever in Patients with Hematological Malignancies. Open Forum Infectious Diseases. Vol. 9
Nirmatrelvir Use and Severe Covid-19 Out-comes during the Omicron Surge

29.8.2022 (Prof. Manuel Battegay)

Arbel R. et al.: Nirmatrelvir Use and Severe Covid-19 Out-comes during the Omicron Surge New Engl. Journal of Med. Vol. 387 2022

Continuous infusion versus intermittent infusion of vancomycin in critically ill patients undergoing continuous venovenous hemofiltration: a prospective interventional study

22.08.2022 (Sabine Kuster)

Xu J. et al.: Continuous infusion versus intermittent infusion of vancomycin in critically ill patients undergoing continuous venovenous hemofiltration: a prospective interventional study BMC Infectious Diseases Published online, 2 August 2022 P. 1-14 2022

Diagnostic parameters of cellular tests for Lyme borreliosis in Europe (VICTORY study): a case-control study

15.8.2022 (Aurélien Martinez)

Baarsma et al.: Diagnostic parameters of cellular tests for Lyme borreliosis in Europe (VICTORY study): a case-control study Lancet Infectious diseases (online) 2022

Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection

08.08.2022 (Flurin Grob)

Zasowski EJ et al.: Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection OFID Vol. 9(3) P. ofab606 2022

Effectiveness of serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study

25.07.2022 (Burgener Anne-Valérie)

Winston EA et al.: Effectiveness of serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study The Lancet Infectious Diseases Vol. 22 P. 1021-1029 2022

Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial

18.07.2022 (Annika Bargetzi)

Adrien Bouglé et al.: Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial Intensive Care Medicine Vol. Jul;48(7) P. 841-849 2022

Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis

11.07.2022 (Richard Kühl)

Bjornevik K. et al.: Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis Science Vol. 375 P. 296-301 2022

Efficacy of 12-months oral itraconazole versus 6-months oral itraconazole to prevent relapses of chronic pulmonary aspergillosis: an open-label, randomised controlled trial in India

04.07.2022 (Pascal Urwyler)

Inderpaul S S et al.: Efficacy of 12-months oral itraconazole versus 6-months oral itraconazole to prevent relapses of chronic pulmonary aspergillosis: an open-label, randomised controlled trial in India Lancet Infectious Diseases Vol. 22 P. 1052-1061 2022

Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit

27.06.2022 (Annika Bargetzi)

Lamontagne F. et al.: Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit NEJM Vol. 386;25 P. 386;25 2022

Real-world trends in incidence of bacterial sexually transmissible infections among gay and bisexual men using HIV pre-exposure prophylaxis (PrEP) in Australia following na-tionwide PrEP implementation: an analysis of sentinel surveillance data

20.06.2022 (Andrea Erba)

Traeger MW: Real-world trends in incidence of bacterial sexually transmissible infections among gay and bisexual men using HIV pre-exposure prophylaxis (PrEP) in Australia following na-tionwide PrEP implementation: an analysis of sentinel surveillance data Lancet Infect Dis. Online ahead of print 2022

Efficacy and safety of intramuscular admin-istration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial

13.06.2022 (Pascal Urwyler)

Montgomery H. et al.: Efficacy and safety of intramuscular admin-istration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial Lancet Respiratory Medicine 2022 Published online 
doi.org/10.1016/ S2213-2600(22)00180-1 

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

30.05.2022 (Benedikt Altermatt)

Sorana Segal-Maurer et al.: Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection N Engl J Med 2022 Vol. 386 P. 1793 - 1803

Antibiotic Therapy for Pseudomonas aeru-ginosa Bloodstream Infections: How Long Is Long Enough?

23.05.2022 (Michelle Baumann)

Fabre V. et al.: Antibiotic Therapy for Pseudomonas aeruginosa Bloodstream Infections: How Long Is Long Enough? Clin Infect Dis Vol. 69 P. 2011-2014 2019

An All-Oral 6-Month Regime for Multidruf-Resistant TB (the Next Study): A Multicenter, Randomized Controlled Trial

16.05.2022 (Justus Baarts)

Esmail A. et al.: An All-Oral 6-Month Regime for Multidruf-Resistant TB (the Next Study): A Multicenter, Randomized Controlled Trial AM J Respir Crit Care Med 2022 Vol. 205 P. 1214-1227

Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19

09.05.2022 (Carla Walti)

Levin M.J. et al.: Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19 NEJM DOI: 10.1056/NEJMoa2116620 2022

Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii

02.05.2022 (Gioele Capoferri)

Falcone M. et al.: Cefiderocol - Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii Antimicrob Agents Chemother 2022 

Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection

11.04.2022 (Silvio Ragozzino)

Eckburg PB et al.: Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection N Engl J Med 2022 Vol. 386 P.1327-1338

Second Booster Vaccine and Covid-19 Mortality in Adults 60 to 100 Years Old

04.04.2022 (Anne-Valérie Burgener)

Ronen Arbel et al.: Second Booster Vaccine and Covid-19 Mortality in Adults 60 to 100 Years Old Preprint. DOI: doi.org/10.21203/rs.3.rs-1478439/v1

Treatment outcome with penicillin G or cloxacillin in penicillin susceptible Staphylococcus aureus bacteraemia - A retrospective cohort study 

28.03.2022 (Benedikt Altermatt)

Hagstrand M. et al.: Treatment outcome with penicillin G or cloxacillin in penicillin susceptible Staphylococcus aureus bacteraemia - A retrospective cohort study International Journal of Antimicrobial Agents Vol. 59 Article 106567 2022

Relationship between serotypes, disease characteristics and 30‑day mortality in adults with invasive pneumococcal disease

21.03.2022 (Michelle Baumann)

Benadji A. et al.: Relationship between serotypes, disease characteristics and 30‑day mortality in adults with invasive pneumococcal disease Infection Vol. 50 P.223/233

Kein Journalclub14.03.2022
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

28.02.2022 (Parham Sendi)

Hammond J et al.: Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 N Eng J Med Online ahead of print. Feb 16. doi: 10.1056/NEJMoa2118542 2022

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

21.02.2022 (Ana Durovic)

CJL Murray et al.: Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis The Lancet Lancet 2022; 399: 629–55 2022

Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge

14.02.2022 (Pascal Urwyler)

Killingley B. et al.: Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge Preprint, Research Square 2022

Fosfomycin vs Ertapenem for Outpatient Treatment of Complicated Urinary Tract Infections: A Multicenter Retrospective Cohort Study

07.02.2022 (Sandra Zingg)

Wald-Dickler N. et al.: Fosfomycin vs Ertapenem for Outpatient Treatment of Complicated Urinary Tract Infections: A Multicenter Retrospective Cohort Study Open Forum Infectious Diseases Volume 9, Issue 1 January 2022

SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection

31.01.2022 (Gioele Capoferri)

Paul Feuerstadt et al.: SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection NEJM

Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results from a Phase 3 Randomized Clinical Trial

24.01.2022 (Carla Walti)

Avery RK et al:  Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results from a Phase 3 Randomized Clinical Trial CID 2021

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

17.01.2022 (Silvio Ragozzino)

Gottlieb RL. Et al.: Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients N Engl J Med doi: 10.1056/NEJMoa2116846. Epub ahead of print. 2021

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico

10.01.2022 (Andreas Neumayr)

Dunkle L.A. et al.: Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico NEJM DOI:10.1056/NEJMoa2116185 2021